Repeat Dose Theophylline
PreclinicalSmall molecule
Repeat Dose Theophylline is one of 53 small molecule programs targeting Hypothermia. It is currently in Preclinical.
2
Indications
1
Total Trials
1
Active Trials
52
Competitors
Pipeline
Status by Indication[3][1]
Competition
Competitive Landscape
178 competitors in Acute Kidney Injury
#DrugCompanyPhaseTrials
1Truphylline
TThe Searle Company Limited Pakistan
Phase 3
Epoetin Beta
RochePhase 3
Crestor
AstraZenecaPreclinical
Lexapro
AbbViePreclinical
Lescol
NovartisPreclinical
Proamatine
TakedaPreclinical
Cymbalta
Alnylam PharmaceuticalsPreclinical
Celexa
AbbViePreclinical
Golytely
BayerPreclinical
PROCRIT
WWim Janssens
Preclinical
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for Repeat Dose Theophylline. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Small molecule[2]
- Highest Phase
- Preclinical[1]
- Company
- MMedical College of Wisconsin